浸润性胶质瘤的关键治疗试验及其对临床实践的影响。
Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice.
作者信息
Lukas Rimas V, Mrugala Maciej M
机构信息
University of Chicago, Department of Neurology (R.V.L.); University of Washington, Department of Neurology (M.M.M.).
出版信息
Neurooncol Pract. 2017 Dec;4(4):209-219. doi: 10.1093/nop/npw016. Epub 2016 Aug 26.
Abstract
The therapeutic landscape of the management of low- and high-grade infiltrating gliomas continues to evolve. Daily clinical decision making in neuro-oncology clinics across the US is frequently challenging, especially for anaplastic and low grade primary brain tumors. The focus of this review is centered on treatments which are approved by the FDA and/or featured in the NCCN Guidelines. Systemic therapy trials using a variety of agents such as temozolomide, bevacizumab, and procarbazine, lomustine, vincristine (PCV), and lastly trials of local therapies including surgical trials using carmustine impregnated wafers as well as trials investigating the administration of tumor treating fields are evaluated. Pivotal trials on the treatment of the primary brain tumors are discussed in detail along with associated correlative studies.
摘要
低级别和高级别浸润性胶质瘤的治疗格局不断演变。在美国各地的神经肿瘤诊所，日常临床决策常常具有挑战性，尤其是对于间变性和低级别原发性脑肿瘤。本综述的重点集中在经美国食品药品监督管理局（FDA）批准和/或被纳入美国国立综合癌症网络（NCCN）指南的治疗方法。评估了使用多种药物的全身治疗试验，如替莫唑胺、贝伐单抗，以及丙卡巴肼、洛莫司汀、长春新碱（PCV）联合化疗，最后还评估了局部治疗试验，包括使用卡莫司汀浸渍晶片的手术试验以及探讨肿瘤治疗电场给药的试验。同时详细讨论了原发性脑肿瘤治疗的关键试验以及相关的相关性研究。
相似文献
1
Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice.浸润性胶质瘤的关键治疗试验及其对临床实践的影响。
Neurooncol Pract. 2017 Dec;4(4):209-219. doi: 10.1093/nop/npw016. Epub 2016 Aug 26.
2
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.丙卡巴肼、洛莫司汀和长春新碱用于复发性高级别胶质瘤。
Cochrane Database Syst Rev. 2017 Jul 26;7(7):CD011773. doi: 10.1002/14651858.CD011773.pub2.
3
One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.替莫唑胺治疗脑胶质瘤 1 年耐受性差：国家神经肿瘤中心的真实世界经验。
BMC Cancer. 2021 Feb 8;21(1):140. doi: 10.1186/s12885-021-07809-5.
4
Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort.放疗联合丙卡巴肼、洛莫司汀和长春新碱与放疗联合替莫唑胺治疗异柠檬酸脱氢酶（IDH）突变型间变性星形细胞瘤的疗效比较：法国POLA队列的回顾性多中心分析
Oncologist. 2021 May;26(5):e838-e846. doi: 10.1002/onco.13701. Epub 2021 Feb 15.
5
Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?丙卡巴肼、洛莫司汀与长春新碱或替莫唑胺：哪种方案更佳？
CNS Oncol. 2015;4(5):341-6. doi: 10.2217/cns.15.36. Epub 2015 Nov 6.
6
High-grade Gliomas.高级别胶质瘤
Continuum (Minneap Minn). 2017 Dec;23(6, Neuro-oncology):1548-1563. doi: 10.1212/CON.0000000000000554.
7
Adults with newly diagnosed high-grade gliomas.新诊断为高级别胶质瘤的成年人。
Curr Treat Options Oncol. 2001 Dec;2(6):507-15. doi: 10.1007/s11864-001-0072-y.
8
Nitrosoureas in the Management of Malignant Gliomas.亚硝脲类药物在恶性脑胶质瘤治疗中的应用
Curr Neurol Neurosci Rep. 2016 Feb;16(2):13. doi: 10.1007/s11910-015-0611-8.
9
Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report.环己亚硝脲、甲基苄肼和长春新碱（PCV）辅助化疗用于间变性胶质瘤放疗后优于卡氮芥：NCOG 6G61最终报告
Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4. doi: 10.1016/0360-3016(90)90096-3.
10
Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.高危低级别胶质瘤的放化疗：替莫唑胺与 PCV 的选择。
Cancer Med. 2020 Jan;9(1):3-11. doi: 10.1002/cam4.2686. Epub 2019 Nov 7.
引用本文的文献
1
Immune Checkpoint Inhibitors in Glioblastoma IDHwt Treatment: A Systematic Review.免疫检查点抑制剂在异柠檬酸脱氢酶野生型胶质母细胞瘤治疗中的应用：一项系统评价
Cancers (Basel). 2024 Dec 12;16(24):4148. doi: 10.3390/cancers16244148.
2
Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?调节胶质母细胞瘤浸润性髓样细胞上的免疫检查点是否是一种可行的治疗策略？
Neuro Oncol. 2025 Jan 12;27(1):33-49. doi: 10.1093/neuonc/noae193.
3
Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma.胶质母细胞瘤肿瘤电场（TTFields）治疗的最新进展。
Oncologist. 2025 Feb 6;30(2). doi: 10.1093/oncolo/oyae227.
4
Global post‑marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011-2022.全球超过 25000 例中枢神经系统恶性肿瘤患者在 2011-2022 年期间接受肿瘤电场治疗的上市后安全性监测。
J Neurooncol. 2024 Aug;169(1):25-38. doi: 10.1007/s11060-024-04682-7. Epub 2024 Jun 29.
5
STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma.STING 激动剂 8803 重编程免疫微环境，增加胶质母细胞瘤临床前模型中的存活率。
J Clin Invest. 2024 Jun 17;134(12):e175033. doi: 10.1172/JCI175033.
6
Glioblastoma Phagocytic Cell Death: Balancing the Opportunities for Therapeutic Manipulation.胶质母细胞瘤吞噬细胞死亡：平衡治疗干预的机会。
Cells. 2024 May 11;13(10):823. doi: 10.3390/cells13100823.
7
The Use of Targeted Cytokines as Cancer Therapeutics in Glioblastoma.靶向细胞因子在胶质母细胞瘤癌症治疗中的应用
Cancers (Basel). 2023 Jul 23;15(14):3739. doi: 10.3390/cancers15143739.
8
Gene Therapy for the Treatment of Malignant Glioma.用于治疗恶性胶质瘤的基因疗法
Adv Oncol. 2021 May;1:189-202. doi: 10.1016/j.yao.2021.02.016. Epub 2021 May 19.
9
Recurrent glioblastoma in elderly: Options and decision for the treatment.老年复发性胶质母细胞瘤：治疗选择与决策
Surg Neurol Int. 2022 Sep 2;13:397. doi: 10.25259/SNI_552_2022. eCollection 2022.
10
Next Steps for Immunotherapy in Glioblastoma.胶质母细胞瘤免疫治疗的下一步措施
Cancers (Basel). 2022 Aug 20;14(16):4023. doi: 10.3390/cancers14164023.
本文引用的文献
1
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.更多是否更好？延长辅助替莫唑胺在新诊断胶质母细胞瘤中的影响：EORTC 和 NRG 肿瘤学/RTOG 的二次分析。
Neuro Oncol. 2017 Aug 1;19(8):1119-1126. doi: 10.1093/neuonc/nox025.
2
Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.NOA - 04关于间变性胶质瘤序贯放化疗采用PCV或替莫唑胺的随机III期试验的长期分析。
Neuro Oncol. 2016 Nov;18(11):1529-1537. doi: 10.1093/neuonc/now133. Epub 2016 Jul 1.
3
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.放疗联合丙卡巴肼、洛莫司汀和长春新碱治疗低级别胶质瘤
N Engl J Med. 2016 Apr 7;374(14):1344-55. doi: 10.1056/NEJMoa1500925.
4
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.替莫唑胺联合肿瘤电场治疗与替莫唑胺单药治疗胶质母细胞瘤的维持治疗：一项随机临床试验。
JAMA. 2015 Dec 15;314(23):2535-43. doi: 10.1001/jama.2015.16669.
5
Glioblastoma care in the elderly.老年胶质母细胞瘤的治疗。
Cancer. 2016 Jan 15;122(2):189-97. doi: 10.1002/cncr.29742. Epub 2015 Nov 30.
6
International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme.国际原子能机构对新诊断为多形性胶质母细胞瘤的老年和/或体弱患者进行放射治疗的随机 III 期研究。
J Clin Oncol. 2015 Dec 10;33(35):4145-50. doi: 10.1200/JCO.2015.62.6606. Epub 2015 Sep 21.
7
Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.前体神经胶质母细胞瘤患者在一线放疗和替莫唑胺基础上加用贝伐单抗可能获得总生存获益：AVAglio试验的回顾性分析
J Clin Oncol. 2015 Sep 1;33(25):2735-44. doi: 10.1200/JCO.2015.61.5005. Epub 2015 Jun 29.
8
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.在新诊断的胶质母细胞瘤中贝伐单抗、替莫唑胺和放疗的随机 III 期研究中的健康相关生活质量。
J Clin Oncol. 2015 Jul 1;33(19):2166-75. doi: 10.1200/JCO.2014.60.3217. Epub 2015 May 26.
9
Risk of surgical site infection in 401 consecutive patients with glioblastoma with and without carmustine wafer implantation.401例连续胶质母细胞瘤患者接受或未接受卡莫司汀晶片植入手术的手术部位感染风险
Neurol Res. 2015 Aug;37(8):717-26. doi: 10.1179/1743132815Y.0000000042. Epub 2015 Apr 28.
10
Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424.替莫唑胺同步放化疗治疗高危低级别胶质瘤的II期研究：放射肿瘤学组0424的初步结果
Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):497-504. doi: 10.1016/j.ijrobp.2014.11.012. Epub 2015 Jan 30.
Zotero 插件